Skip to main navigation Skip to search Skip to main content

A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults with FLT3 mutated or Spliceosome mutated or Spliceosome mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Project: Research

Project Details

StatusActive
Effective start/end date28/08/24 → 28/08/29

Keywords

  • clinical trial
  • Acute Myeloid Leukemia (AML)
  • haematological malignancy
  • FLT3 inhibitor

Clinical Trial Phase

  • Phase I